Psychedelic Research Australia | Natural MedTech

Legal Manufacture of Australian Psychoactive Plants and Fungi for Research

Stay Up to Date

1 in 8

Australians are on Antidepressants.

30%

of people on Antidepressants are treatment resistant.

$180 Billion

mental ill-health and suicide are costing Australia up to $180 billion per year

Supporters, Collaborators, Partners

Innovating solutions to translate evidence based psychedelic therapies through research in the most accessible, thorough and accurate way possible.

Why?

We believe people deserve better than to live with symptom management when there are potentially more effective and healthier treatment options. Our mission is to break the symptom management cycle that’s all too prevalent in mental healthcare.

Manufacturing in Melbourne

We are investing in a research and development laboratory coupled with current Good Manufacturing Practice (cGMP) capabilities to manufacture psychedelic molecules for research.

Our Scientific, Medical, Regulatory, University and Industry collaborators are experts and pioneers in their respective fields.

Our Team

University Partners

We are actively harnessing Australia's exemplary scientific community and creating robust collaborations to develop evidence based medications for conditions where little to no effective pharmacological therapy is currently available.

Our Research

Medicine Manufacture

Australia's first laboratory specifically designed to research and manufacture psychoactive drugs.
We apply genetic based approaches to mycology and fermentation. Our manufacturing processes are projected to be %70-90% cheaper then other methods of production,

Our Lab

Mindfulness Clinic

Psychiatry & Psychology

+
Mindfulness, Meditation, Breathwork, Yoga, VR.

Medically supervised, legal access to evidence based drug-Assisted Psychotherapy is becoming increasingly available for multiple conditions, throughout Australia through clinical trials.

Experiential Therapies

Clinical Research

Psychedelic research is being recognised as valid research by the Australian Government.

The allocation of $15 Million by the Australian Government to further research psychedelics as medicines opens pathways to rigorous clinical trials throughout the country.

Find out if you are potentially a suitable candidate to be a trial participant.

Suitability

We support research in the following areas

Clinical Research Suitability

DEPRESSION
POST-TRAUMATIC STRESS DISORDER
ANXIETY
PALLIATIVE CARE
ADDICTION
SUICIDAL IDEATION
TRAUMATIC BRAIN INJURY (TBI) - concussion
COMA RESURRECTION THERAPY (CRT)
MOTOR NEURON DISEASE
STROKE RECOVERY
SEXUAL DYSPHORIA
AUTO IMMUNE ISSUES
THE GUT BRAIN AND MICROBIOME
POSTNATAL DEPRESSION
CHRONIC PAIN
NEUROGENESIS
MICRODOSING

Acknowledgement of country

Natural MedTecH acknowledges the Traditional Owners of the unceded land where we work and live, specifically the people of the Woi worung, Boon wurrung language groups of the eastern kulin nation and the Balardung, Nyaki-Nyaki Birrbay (Biripi) people. We pay our respects to Elders past, present and emerging. We celebrate the stories, culture and traditions of Aboriginal and Torres Strait Islanders of all communities who also work and live on this land.

Social Responsibility

We work with Australian native species and have consulted varies elders and community members around the traditional use of the plants and fungi that we study and are developing. We we haven't been told of any traditional use of these plants and fungi but welcome conversations with indigenous to share with us, and the world your story and medicine. We are interested in the recovery and evolution of indigenous knowledge.

We believe in working towards creating circular and sustainable systems and believe that evidence based medicine should be a universal right and not only accessible not only to those with the financial means. With this reality in mind, we are actively innovating new strategies and seeking partners to help facilitate the accessibility of health services to marginalized groups to ensure the benefits of emerging therapies are not the exclusive domain to the of the privileged.